Sonnet BioTherapeutics Holdings, Inc.
SONN · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | 0.00 | 0.01 |
| FCF Yield | -196.36% | -732.42% | -447.65% | -151.79% |
| EV / EBITDA | -0.37 | -0.05 | -0.12 | 0.51 |
| Quality | ||||
| ROIC | 3,339.05% | -36,863.45% | 1,299.73% | -112.07% |
| Gross Margin | 100.00% | 100.00% | -6,027.86% | 100.00% |
| Cash Conversion Ratio | 0.80 | 1.16 | 1.13 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 89.13% | -62.38% | -32.64% | – |
| Free Cash Flow Growth | 60.49% | 23.79% | -26.72% | -43.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.11 | 0.09 | 1.10 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 14,933.88 | 1,942.42 | -17,852.09 | 0.00 |